108 related articles for article (PubMed ID: 9138997)
1. [The value of CA 125 levels in serum, peritoneal fluid and tumor in women with ovarian cancer].
Markowska J; Wilkoszarska J
Ginekol Pol; 1996 Jul; 67(7):352-6. PubMed ID: 9138997
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
Chechlinska M; Kaminska J; Markowska J; Kramar A; Steffen J
Int J Biol Markers; 2007; 22(3):172-80. PubMed ID: 17922459
[TBL] [Abstract][Full Text] [Related]
3. CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.
Ismail MA; Rotmensch J; Mercer LJ; Block BS; Salti GI; Holt JA
J Reprod Med; 1994 Jul; 39(7):510-2. PubMed ID: 7966039
[TBL] [Abstract][Full Text] [Related]
4. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
Carico E; Chicchirichi R; Atlante M; Giovagnoli M; Vecchione A
Anticancer Res; 1995; 15(2):631-4. PubMed ID: 7763049
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
6. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
Zaucha R; Kobierska A
Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
[TBL] [Abstract][Full Text] [Related]
7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
9. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R; Nustad K
Gynecol Oncol; 1995 May; 57(2):183-7. PubMed ID: 7729731
[TBL] [Abstract][Full Text] [Related]
10. Tissue quantification of CA 125 in epithelial ovarian cancer.
de la Cuesta R; Maestro ML; Solana J; Vidart JA; Escudero M; Iglesias E; Valor R
Int J Biol Markers; 1999; 14(2):106-14. PubMed ID: 10399630
[TBL] [Abstract][Full Text] [Related]
11. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer.
Boran N; Kayikçioğlu F; Yalvaç S; Tulunay G; Ekinci U; Köse MF
Gynecol Obstet Invest; 2000; 49(4):272-4. PubMed ID: 10828712
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer.
Yüce K; Baykal C; Genç C; Al A; Ayhan A
Eur J Gynaecol Oncol; 2001; 22(3):228-32. PubMed ID: 11501779
[TBL] [Abstract][Full Text] [Related]
13. CA 125 in peritoneal fluid: reliable values at high dilutions.
Barbati A; Anceschi MM; Di Renzo GC; Cosmi EV
Obstet Gynecol; 1992 Jun; 79(6):1011-5. PubMed ID: 1579297
[TBL] [Abstract][Full Text] [Related]
14. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
15. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
[TBL] [Abstract][Full Text] [Related]
17. [Role of second-look surgery in treatment of ovarian neoplasms].
Markowska J; Szewierski Z; Roszak A; Niecewicz R
Ginekol Pol; 1996 Apr; 67(4):200-4. PubMed ID: 8846933
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
[TBL] [Abstract][Full Text] [Related]
19. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
20. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
